ANXA1 and Alzheimer disease: Recombinant human annexin A1 (hrANXA1) was demonstrated to lower amyloid-β levels in an AD mice model [151] whereas annexin A5, whose cerebrospinal fluid level was reported to match disease severity in AD patients, was implicated as a biomarker in AD [152].